Pretreatment of metanephric mesenchymal cells with catalpol mitigates acute kidney injury through VEGF-A secretion via multiple mechanisms - PubMed
3 hours ago
- #Acute Kidney Injury
- #VEGF-A Signaling
- #Stem Cell Therapy
- Catalpol pretreatment of metanephric mesenchymal cells (MMCs-cata) enhances therapeutic efficacy in a mouse model of cisplatin-induced acute kidney injury (AKI).
- MMCs-cata improve renal function by reducing inflammation, oxidative stress, and necroptosis, with elevated VEGF-A secretion via activation of the canonical Wnt pathway.
- Protective effects depend on VEGF-A/VEGFR2 interaction, involving p38 pathway activation and STAT3 pathway inhibition in renal tubular epithelial cells.
- The study suggests a novel approach combining traditional Chinese medicine components with stem cell therapy for AKI management.